

Planning and management to control and eliminate HTLV-1 infection in Iran

محل انتشار:

مجله علوم پایه پزشکی ایران, دوره 24, شماره 3 (سال: 1400)

تعداد صفحات اصل مقاله: 3

نویسندگان: Reza Boostani - Department of Neurology, Mashhad University of Medical Sciences, Mashhad, Iran

Nasim Lotfinejad - Department of Research, Faculty of Medicine, Mashhad University of medical sciences, Mashhad, Iran

Fariba Zemorshidi - Department of Neurology, Mashhad University of Medical Sciences, Mashhad, Iran

Zohreh Vahidi - Immunology Research Centre, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran

Seyed Abdolrahim Rezaee - Immunology Research Centre, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran

Reza Farid - Allergy Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran

Houshang Rafatpanah - Immunology Research Centre, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran

خلاصه مقاله:

Prevention and treatment of the Human T-cell leukemia virus, type 1 (HTLV-1) which was discovered nearly \$\mathbf{F}_0\$ years ago, still remain challenging. The reported high prevalence of HTLV-1 in some countries around the world triggered an open letter to the World Health Organization (WHO), urging action against HTLV-1 infection in Yola. This highlights the importance of virus elimination strategies to eradicate HTLV-1 infection. In Iran, we have documented our experiences with the virus in order to achieve and promote the possible ways to manage, control, and eliminate HTLV-1. Although there has been considerable progress apropos of HTLV-1, a series of additional challenges need to be tackled to .control HTLV-1 infection in Iran

کلمات کلیدی: ATL HAM/TSP HTLV, ۱ Prevention Treatments

لینک ثابت مقاله در پایگاه سیویلیکا:

https://civilica.com/doc/1186927



